Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy

類似資料

• Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
  著者:: Ritter, Violetta, 等
  出版事項: (2021)
• ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
  著者:: Li, Ji-Yu, 等
  出版事項: (2012)
• Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL
  著者:: Shi, Jue, 等
  出版事項: (2011)
• Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction
  著者:: Tareq Saleh, 等
  出版事項: (2020-10-01)
• Role of SGK1 for fatty acid uptake, cell survival and radioresistance of NCI-H460 lung cancer cells exposed to acute or chronic cycling severe hypoxia
  著者:: Matschke, Johann, 等
  出版事項: (2016)